Database Study Design
WHY IS THIS IMPORTANT?
Randomized controlled trials (RCTs) are exceedingly expensive and time consuming, and often not feasible. You can obtain the same answers at a fraction of the time and cost by undertaking a database study.
Database studies provide a solution for generating comparative cost data when you’re only running single-arm studies, generating important inputs for health economic models when literature is sparse, and quantifying the cost-benefit of utilizing your product.
You must select the right data sources and know how to integrate data to conduct a successful database study.
DID YOU KNOW?
Administrative databases can provide comparator data.
It’s not only critical that you select the right data sources when conducting a database study, but you must also make sure you have the appropriate inclusion and exclusion criteria defined.
There can be drawbacks to incorporating databases into your study design. For instance, different sources of data can show considerable differences in outcome definitions, data collection and management methods, and more. Additionally, adverse events can be underreported in administrative claims databases. Therefore, designing and analyzing these studies requires expertise.
HOW WE CAN HELP
By incorporating administrative databases into your study design, our experts can identify and integrate data from appropriate sources (after carefully defining patient characteristics, outcomes, and costs for the data pull) and generate your evidence in a fraction of the time while competitors sit and wait on completion of their pivotal trials.
Our experts will define your inclusion and exclusion criteria to ensure the right patients get included with a large enough sample size.
If you require assistance analyzing data sets from your own databases, we offer data analysis services and can develop, set up, and maintain databases and handle data entry and QC as needed.
Insights
The Three Roles Precision Medicine Plays in Advancing Health Equity
The Three Roles Precision Medicine Plays in Advancing Health Equity We're delighted for our Founder & [...]
Is Your LDT Headed Down a Dangerous Path?
Is Your LDT Headed Down a Dangerous Path? Does your go-to-market (GTM) plan include using existing test [...]
>75% of Medtech Startups Fail & This is Why
What Leads to Company Underperformance & Failure? As a medtech company operating in such a nuanced [...]
Waiting is costly.